Приказ основних података о документу
Association of pentraxin-3, galectin-3 and matrix metalloproteinase-9/TIMP-1 with cardiovascular risk in renal disease patients
dc.creator | Miljković, Milica | |
dc.creator | Stefanović, Aleksandra | |
dc.creator | Bogavac-Stanojević, Nataša | |
dc.creator | Simić-Ogrizović, Sanja | |
dc.creator | Dumić, Jerka | |
dc.creator | Cerne, Darko | |
dc.creator | Jelić-Ivanović, Zorana | |
dc.creator | Kotur-Stevuljević, Jelena | |
dc.date.accessioned | 2019-09-02T11:59:33Z | |
dc.date.available | 2019-09-02T11:59:33Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 0353-9466 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/2886 | |
dc.description.abstract | Inflammation, apoptosis and extracellular remodeling play significant roles in cardiovascular disease (CVD) underlying the major causes of mortality in renal patients. In 19 pre-dialysis patients, 21 dialysis patients and 20 control subjects, the concentrations of pentraxin-3, galectin-3, MMP-9 and TIMP-1 were determined by ELISA. CVD risk was calculated according to the Framingham risk score algorithm. Pentraxin-3 was increased in renal patients compared to healthy controls (p lt 0.001). In contrast, galectin-3 was reduced in hemodialysis patients compared to pre-dialysis patients and controls (p lt 0.001). In addition, MMP-9 and TIMP-1 were elevated in renal patients compared to controls (p lt 0.01 and p lt 0.001, respectively). Logistic regression analyses disclosed associations of galectin-3, MMP-9, pentraxin-3 and glomerular filtration with calculated CVD risk score. Combined testing of pentraxin-3, galectin-3, MMP-9 and glomerular filtration rate can discriminate renal patients with high and low risk of a coronary event. | en |
dc.publisher | Sestre Milosrdnice Univ Hospital, Zagreb | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175035/RS// | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.source | Acta Clinica Croatica | |
dc.subject | Kidney diseases | en |
dc.subject | Pentraxin-3 | en |
dc.subject | Galectin-3 | en |
dc.subject | Matrix-metalloproteinase-9 | en |
dc.subject | Tissue inhibitor of matrix metalloproteinase-1 | en |
dc.subject | Risk factors | en |
dc.subject | Risk assessment | en |
dc.subject | Cardiovascular diseases | en |
dc.title | Association of pentraxin-3, galectin-3 and matrix metalloproteinase-9/TIMP-1 with cardiovascular risk in renal disease patients | en |
dc.type | article | |
dc.rights.license | BY-NC-ND | |
dcterms.abstract | Котур-Стевуљевић, Јелена; Симић-Огризовић, Сања; Јелић-Ивановић, Зорана; Богавац-Станојевић, Наташа; Миљковић, Милица; Стефановић, Aлександра; Думић, Јерка; Церне, Дарко; | |
dc.citation.volume | 56 | |
dc.citation.issue | 4 | |
dc.citation.spage | 673 | |
dc.citation.epage | 680 | |
dc.citation.other | 56(4): 673-680 | |
dc.citation.rank | M23 | |
dc.identifier.wos | 000426891900014 | |
dc.identifier.doi | 10.20471/acc.2017.56.04.14 | |
dc.identifier.pmid | 29590722 | |
dc.identifier.scopus | 2-s2.0-85042388871 | |
dc.identifier.fulltext | https://farfar.pharmacy.bg.ac.rs//bitstream/id/1509/2884.pdf | |
dc.type.version | publishedVersion |